loading
Schlusskurs vom Vortag:
$12.05
Offen:
$11.95
24-Stunden-Volumen:
34,102
Relative Volume:
0.46
Marktkapitalisierung:
$316.12M
Einnahmen:
$26.00M
Nettoeinkommen (Verlust:
$-219.71M
KGV:
-0.2446
EPS:
-49.8
Netto-Cashflow:
$-51.37M
1W Leistung:
-10.31%
1M Leistung:
+24.80%
6M Leistung:
-36.10%
1J Leistung:
-27.72%
1-Tages-Spanne:
Value
$11.95
$12.61
1-Wochen-Bereich:
Value
$11.80
$13.80
52-Wochen-Spanne:
Value
$8.46
$26.50

Cartesian Therapeutics Inc Stock (RNAC) Company Profile

Name
Firmenname
Cartesian Therapeutics Inc
Name
Telefon
301-348-8698
Name
Adresse
7495 NEW HORIZON WAY, FREDERICK
Name
Mitarbeiter
66
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
RNAC's Discussions on Twitter

Vergleichen Sie RNAC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RNAC
Cartesian Therapeutics Inc
12.18 352.46M 26.00M -219.71M -51.37M -49.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-09 Eingeleitet Wedbush Outperform
2024-12-19 Eingeleitet BTIG Research Buy
2024-08-06 Eingeleitet TD Cowen Buy
2024-07-02 Herabstufung Oppenheimer Outperform → Perform
2024-06-04 Eingeleitet Oppenheimer Outperform
2024-05-24 Eingeleitet Mizuho Buy
2024-04-23 Bestätigt H.C. Wainwright Buy
2024-04-23 Eingeleitet Leerink Partners Outperform
2023-08-18 Herabstufung SVB Securities Outperform → Market Perform
2022-06-14 Bestätigt Needham Buy
2022-06-06 Eingeleitet SVB Leerink Outperform
2021-06-15 Eingeleitet BTIG Research Buy
2021-01-26 Hochstufung Mizuho Neutral → Buy
2020-10-01 Herabstufung Mizuho Buy → Neutral
2020-10-01 Herabstufung William Blair Outperform → Mkt Perform
2020-06-12 Herabstufung Stifel Buy → Hold
2020-04-28 Eingeleitet H.C. Wainwright Buy
2020-01-29 Eingeleitet Cantor Fitzgerald Overweight
2020-01-21 Eingeleitet William Blair Outperform
2018-06-27 Eingeleitet Janney Buy
2017-03-30 Bestätigt UBS Buy
Alle ansehen

Cartesian Therapeutics Inc Aktie (RNAC) Neueste Nachrichten

pulisher
03:36 AM

Cartesian Therapeutics Inc. Stock Analysis and ForecastBreakout profit opportunities - Autocar Professional

03:36 AM
pulisher
03:09 AM

Is Cartesian Therapeutics Inc. a good long term investmentStrongest growth potential - Autocar Professional

03:09 AM
pulisher
Jul 22, 2025

What drives Cartesian Therapeutics Inc. stock priceRapid growth trajectories - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Cartesian Therapeutics Inc. stockFree Stock Market Forecast Reports - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What makes Cartesian Therapeutics Inc. stock price move sharplyFree Stock Market Swing Trading Strategies - Newser

Jul 22, 2025
pulisher
Jul 22, 2025

Multiple Myeloma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics - MenaFN

Jul 22, 2025
pulisher
Jul 15, 2025

Why Cartesian Therapeutics Inc. stock attracts strong analyst attentionCarefully Curated High Return Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Cartesian Therapeutics Inc. stock performs during market volatilityShort Squeeze Radar - Newser

Jul 15, 2025
pulisher
Jul 12, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $40.00 Average Price Target from Analysts - Defense World

Jul 12, 2025
pulisher
Jul 12, 2025

What is Wedbush’s Estimate for RNAC Q2 Earnings? - Defense World

Jul 12, 2025
pulisher
Jul 11, 2025

Cartesian Therapeutics Advances mRNA CAR T-cell Therapy for Myasthenia Gravis - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

Wedbush Initiates Coverage on Cartesian Therapeutics (NASDAQ:RNAC) - Defense World

Jul 11, 2025
pulisher
Jul 10, 2025

CartesianAutoimmune Cell Therapy Excites, But Reality Bites (NASDAQ:RNAC) - Seeking Alpha

Jul 10, 2025
pulisher
Jul 09, 2025

Wedbush initiates coverage on Cartesian Therapeutics stock with Outperform rating - Investing.com Canada

Jul 09, 2025
pulisher
Jul 09, 2025

Cartesian stock up as Wedbush becomes bullish (RNAC:NASDAQ) - Seeking Alpha

Jul 09, 2025
pulisher
Jul 09, 2025

Cartesian Therapeutics' 15min chart sees KDJ Golden Cross, bullish Marubozu formation. - AInvest

Jul 09, 2025
pulisher
Jun 30, 2025

Cartesian Therapeutics, Inc.(NasdaqGM: RNAC) added to Russell 3000 Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 28, 2025

What caused RNAC's earnings to miss forecasts in Q4 2023? - AInvest

Jun 28, 2025
pulisher
Jun 26, 2025

Rhumbline Advisers Grows Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Jun 26, 2025
pulisher
Jun 21, 2025

We're Not Very Worried About Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate - Yahoo Finance

Jun 21, 2025
pulisher
Jun 18, 2025

Myasthenia Gravis Market to Expand Significantly by 2034, States DelveInsight Report | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC - The Globe and Mail

Jun 18, 2025
pulisher
Jun 18, 2025

IBM Introduces Industry-First Software to Unify Agentic Governance and Security - The Globe and Mail

Jun 18, 2025
pulisher
Jun 16, 2025

Cartesian Therapeutics holds annual stockholders meeting By Investing.com - Investing.com South Africa

Jun 16, 2025
pulisher
Jun 16, 2025

Cartesian Therapeutics holds annual stockholders meeting - Investing.com

Jun 16, 2025
pulisher
Jun 16, 2025

Cartesian Therapeutics Holds Annual Stockholders Meeting - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Acquired by Bank of America Corp DE - Defense World

Jun 16, 2025
pulisher
Jun 14, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Jun 14, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Reduces Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Jun 13, 2025
pulisher
Jun 11, 2025

Equities Analysts Offer Predictions for RNAC FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 05, 2025

Nuveen Asset Management LLC Buys 47,889 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire

Jun 04, 2025
pulisher
Jun 03, 2025

Cartesian Therapeutics Announces New Employment Inducement Grants | RNAC Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Cartesian Therapeutics (RNAC) Issues Inducement Stock Options to New Employees | RNAC Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Cartesian Therapeutics Awards 26,350 Stock Options to Key New Hires in Autoimmune Disease Research - Stock Titan

Jun 03, 2025
pulisher
Jun 03, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

H.C. Wainwright maintains buy rating on Cartesian Therapeutics stock By Investing.com - Investing.com Nigeria

Jun 02, 2025
pulisher
Jun 01, 2025

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis - mx.advfn.com

Jun 01, 2025

Finanzdaten der Cartesian Therapeutics Inc-Aktie (RNAC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Cartesian Therapeutics Inc-Aktie (RNAC) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
English Emily
Chief Operations Officer
Apr 15 '25
Option Exercise
3.30
7,500
24,750
47,726
SPRINGER TIMOTHY A
Director
Apr 10 '25
Buy
10.47
48,595
508,751
620,175
SPRINGER TIMOTHY A
Director
Apr 09 '25
Buy
9.43
41,782
393,947
571,580
SPRINGER TIMOTHY A
Director
Apr 11 '25
Buy
10.77
36,338
391,455
656,513
SPRINGER TIMOTHY A
Director
Apr 10 '25
Buy
10.47
8,575
89,773
8,637,273
SPRINGER TIMOTHY A
Director
Apr 09 '25
Buy
9.43
7,373
69,517
8,628,698
SPRINGER TIMOTHY A
Director
Apr 11 '25
Buy
10.77
6,412
69,074
8,643,685
SPRINGER TIMOTHY A
Director
Mar 20 '25
Buy
15.59
54,889
855,593
8,621,325
SPRINGER TIMOTHY A
Director
Mar 19 '25
Buy
14.97
20,234
302,962
8,566,436
SPRINGER TIMOTHY A
Director
Mar 18 '25
Buy
14.42
14,740
212,599
8,546,202
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):